Jazz Pharmaceuticals Exercised its Option to Advance Zymeworks' Zanidatamab for Cancer Patients
Shots:
- Zymeworks to receive $325M one-time fees, ~$525M upon achievement of regulatory milestones, ~$862.5M in commercial milestones representing a total deal value of ~$1.76B & royalty’s b/w 10% & 20% on Jazz's net sales. Jazz exercised its option to continue with its exclusive development & commercialization rights to zanidatamab in the US, EU, Japan & all other territories Ex- Asia/Pacific territories
- In the P-IIb trial (HERIZON-BTC-01), 41.3% of patients achieved ORR in HER2-amplified BTC, m-DoR was 12.9mos. The safety profile was consistent with prior reported monotx. studies with no new safety signals
- Zanidatamab is a bispecific Ab developed from Zymeworks' Azymetric platform. Zymeworks collaborated with Jazz & BeiGene to advance zanidatamab in multiple trials for solid tumors.
Ref: Jazz Pharmaceuticals | Image: Jazz Pharmaceuticals
Related Posts :- Zymeworks' Zanidatamab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Biliary Tract Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
